INM InMed Company Current Liabilities

Graphic logo of InMed (INM)

InMed Pharmaceuticals (INM) has optimized production by outsourcing synthesis to third-party partners while maintaining control over its unique yeast strains. The business is independent of economic cycles or seasonality, relying instead on scientific progress, as reflected in the price chart on GURU.Markets, where the metric stands at 0.00. InMed Pharmaceuticals (INM) has earned trust as a developer of innovative therapies for skin and vision organs.

INM (inmedpharma.com) Current Liabilities history from 07/04/2022 to 10/30/2026

Analytical breakdowns for InMed (INM)

- current quotes and average value forecast:
Price Chart InMed Pharmaceuticals Inc.|INM - Average Forecast Price
- market capitalization data:
Market Valuation InMed Pharmaceuticals Inc.|INM - Value Adjusted for Debt and Cash
- balance sheet net asset value indicators:
Book Value per Share InMed Pharmaceuticals|INM - Net Asset Value|Market Capitalization to Book Value Ratio inmedpharma.com|INM - Company Total Assets
- debt obligations and liquidity statistics:
Debt to Equity InMed Pharmaceuticals|INM - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity InMed Pharmaceuticals|INM - Company Total Debt|Debts to Book Capitalization InMed Pharmaceuticals Inc.|INM - Long-Term Debt Volume|Company Short-Term Debt InMed Pharmaceuticals|Quick Liquidity inmedpharma.com
- net income and valuation multiples indicators:
INM - Net Income
Initial company analysis:InMed Pharmaceuticals Inc. (INM)
Mass-produced product of InMed Pharmaceuticals

This indicator aggregates all financial obligations of InMed Pharmaceuticals (INM) maturing within one year, allowing for an assessment of current liquidity and default risk. By analyzing the volume of short-term debt capital, an investor determines the biopharmaceutical company's ability to fund laboratory research without emergency fundraising, taking into account the issuer's minimal expenditures on environmental infrastructure.

Competitors of InMed Pharmaceuticals

INDV - Company Short-Term Debt|Short-Term Debt Collegium Pharma|CRON (Cronos) - Company Current Liabilities|Canopy Growth Corp. - Company Short-Term Loans and Borrowings|HITI (High Tide Inc.) - Company Short-Term Debts|Aurora - Current Liabilities|Company Short-Term Debts ACHV|Company Short-Term Debts skyebioscience.com (SKYE)|Company Short-Term Debt Anebulo ANEB|Company Short-Term Loans and Borrowings INCR|NTRB - Company Short-Term Debt|Nasus Pharma Ltd (NSRX) - Company Current Liabilities|IGC: Company Short-Term Debts|MIRA - Short-Term Debt Volume|Company Short-Term Debt Flora Growth Corporation|Company Short-Term Indebtedness IMCC (IMC)|Company Short-Term Debt Adial Pharmaceuticals (ADIL)|Company Current Liabilities artelobio.com ARTL|Company Short-Term Debts ENSC (Ensysce Biosciences, Inc.)|Titan Pharmaceuticals Inc. (TTNP) - Short-Term Debt|Greenlane Holdings Inc - Company Short-Term Debts|AKAN (Akanda Inc) - Company Short-Term Indebtedness|ENVB (Enveric Biosciences) - Company Current Liabilities|Bright Green Corporation - Company Short-Term Loans and Borrowings|Company Short-Term Debt Hempacco